Dilated cardiomyopathy

Four Decades of Saving Kids' Hearts: Stanford Children's Health Celebrates its 500th Pediatric Heart Transplant

Retrieved on: 
Monday, December 13, 2021

STANFORD, Calif., Dec. 13, 2021 /PRNewswire/ -- Stanford Children's Health , with Lucile Packard Children's Hospital Stanford at its center, is celebrating its 500th pediatric heart transplant.

Key Points: 
  • STANFORD, Calif., Dec. 13, 2021 /PRNewswire/ -- Stanford Children's Health , with Lucile Packard Children's Hospital Stanford at its center, is celebrating its 500th pediatric heart transplant.
  • This holiday season, 14-year-old Mackenzie Collins , the 500th Stanford Children's Health pediatric heart recipient, will be celebrating a healthy heart at home with her family.
  • It took a multidisciplinary team of pediatric heart surgeons , transplant cardiologists, nurses , pediatric anesthesiologists , surgical technicians, transport, and transplant specialists to achieve the successfulsix-hour open-heart surgery transplant.
  • 2020: Stanford Children's Health performed 24 heart transplants and implanted 18 ventricular assist devices , to extend patients' lives until they receive a donor heart.

Global Congestive Heart Failure (CHF) Market Insights, Epidemiology and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 3, 2021

The "Congestive Heart Failure (CHF) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Congestive Heart Failure (CHF) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Congestive Heart Failure (CHF) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Congestive Heart Failure (CHF) market size from 2018 to 2030.
  • In 2020, the estimated cases of acute heart failure and chronic heart failure in US were 1,548,936 and 3,614,183, respectively.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Congestive Heart Failure market.

Congestive Heart Failure (CHF) Epidemiology Forecast Report 2021-2030 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Monday, November 29, 2021

The "Congestive Heart Failure (CHF) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Congestive Heart Failure (CHF) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Congestive Heart Failure (CHF) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the HF, historical and forecasted epidemiology as well as the HF trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Total Diagnosed Prevalent Cases of Heart Failure (HF) in the 7MM was found to be 12,602,028 in 2020, which is expected to grow during the study period (2018-2030).
  • In 2020, the estimated cases of acute heart failure and chronic heart failure in US were 1,548,936 and 3,614,183, respectively.

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Retrieved on: 
Tuesday, September 14, 2021

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

$304.5 Million Worldwide Dilated Cardiomyopathy Therapeutics Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 16, 2020

The "Dilated Cardiomyopathy Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dilated Cardiomyopathy Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 137-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • The U.S. Market is Estimated at $89.7 Million, While China is Forecast to Grow at 4.2% CAGR
    The Dilated Cardiomyopathy Therapeutics market in the U.S. is estimated at US$89.7 Million in the year 2020.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$45.8 Million by the year 2027.

Global Dilated Cardiomyopathy Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 8, 2020

The "Dilated Cardiomyopathy (DCM) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dilated Cardiomyopathy (DCM) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the disease, historical and forecasted Dilated Cardiomyopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Dilated Cardiomyopathy?
  • Quantify patient populations in the global Dilated Cardiomyopathy market to improve product design, pricing, and launch plans
    The Dilated Cardiomyopathy Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies.

MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy

Retrieved on: 
Wednesday, September 9, 2020

Danicamtiv is MyoKardias most advanced clinical candidate being developed for the treatment of genetic dilated cardiomyopathy (DCM) and other targeted populations with conditions of reduced systolic function.

Key Points: 
  • Danicamtiv is MyoKardias most advanced clinical candidate being developed for the treatment of genetic dilated cardiomyopathy (DCM) and other targeted populations with conditions of reduced systolic function.
  • MyoKardias Phase 2 study of danicamtiv will enroll patients with DCM with documented genetic variants of MYH7 or titin.
  • MyoKardia intends to advance danicamtiv in further clinical studies to characterize clinical benefit, starting with a Phase 2 clinical trial in patients with genetic dilated cardiomyopathy.
  • Voors, et al, European Journal of Heart Failure, 2020
    Sinagra, et al, (editors), Dilated Cardiomyopathy: From Genetics to Clinical Management, Springer 2019
    Lund et al.

Dilated Cardiomyopathy (DCM) Market Insights and Outlook 2017-2030 - Epidemiology, Pipeline, Approved & Emerging Drugs, Competitive Intelligence

Retrieved on: 
Friday, August 21, 2020

The Dilated Cardiomyopathy market report provides current treatment practices, emerging drugs, Dilated Cardiomyopathy market share of the individual therapies, current and forecasted Dilated Cardiomyopathy market size from 2017 to 2030 segmented by seven major markets.

Key Points: 
  • The Dilated Cardiomyopathy market report provides current treatment practices, emerging drugs, Dilated Cardiomyopathy market share of the individual therapies, current and forecasted Dilated Cardiomyopathy market size from 2017 to 2030 segmented by seven major markets.
  • The Dilated Cardiomyopathy epidemiology division provides the insights about historical and current Dilated Cardiomyopathy patient pool and forecasted trend for each seven major countries.
  • Drug chapter segment of the Dilated Cardiomyopathy report encloses the detailed analysis of Dilated Cardiomyopathy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
  • The publisher performs Competitive and Market Intelligence analysis of the Dilated Cardiomyopathy Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc.

Worldwide Dilated Cardiomyopathy (DCM) Market Insights, Epidemiology and Forecast - 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 20, 2020

The "Dilated Cardiomyopathy (DCM) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dilated Cardiomyopathy (DCM) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines report has been added to ResearchAndMarkets.com's offering.
  • The Dilated Cardiomyopathy market report provides current treatment practices, emerging drugs, Dilated Cardiomyopathy market share of the individual therapies, current and forecasted Dilated Cardiomyopathy market size from 2017 to 2030 segmented by seven major markets.
  • The Dilated Cardiomyopathy epidemiology division provides the insights about historical and current Dilated Cardiomyopathy patient pool and forecasted trend for each seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Dilated Cardiomyopathy epidemiology segmented as [Total Prevalent Population of Dilated Cardiomyopathy, Total Diagnosed Population of Dilated Cardiomyopathy, Familial and non-familial cases of Dilated Cardiomyopathy, Gender-Specific Cases of Dilated Cardiomyopathy, and Total Treated Cases of Dilated Cardiomyopathy] scenario of Dilated Cardiomyopathy in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

2020 Dilated Cardiomyopathy Pipeline Research Monitor - ResearchAndMarkets.com

Retrieved on: 
Monday, July 27, 2020

The "Dilated Cardiomyopathy Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dilated Cardiomyopathy Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • The Dilated Cardiomyopathy pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
  • This Dilated Cardiomyopathy pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
  • The competitive intelligence report on Dilated Cardiomyopathy presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Dilated Cardiomyopathy pipeline.